Georgiou Panagiotis, Tan Emile, Gouvas Nikolaos, Antoniou Anthony, Brown Gina, Nicholls R John, Tekkis Paris
Department of Biosurgery and Surgical Technology, Imperial College, Chelsea and Westminster Campus, London, UK.
Lancet Oncol. 2009 Nov;10(11):1053-62. doi: 10.1016/S1470-2045(09)70224-4. Epub 2009 Sep 18.
Lateral pelvic lymph-node metastases occur in 10-25% of patients with rectal cancer, and are associated with higher local recurrence and reduced survival rates. A meta-analysis was undertaken to assess the value of extended lateral pelvic lymphadenectomy in the operative management of rectal cancer.
We searched Medline, Embase, Ovid, Cochrane Library, and Google Scholar for studies published between 1965 and 2009 that compared extended lymphadenectomy (EL) with standard rectal resection. 20 studies, which included 5502 patients from one randomised, three prospective non-randomised, and 14 retrospective case-control studies published between 1984 and 2009, met our search criteria and were assessed. 2577 patients underwent EL and 2925 underwent non-EL for rectal cancer. Random and fixed-effects meta-analytical models were used where indicated, and between-study heterogeneity was assessed. End-points evaluated included peri-operative outcomes, 5-year survival and recurrence rates.
Operating time was significantly longer in the EL group by 76.7 min (95% CI 18.77-134.68; p=0.0096). Intra-operative blood loss was greater in the EL group by 536.5 mL (95% CI 353.7-719.2; p<0.0001). Peri-operative mortality (OR 0.81, 95% CI 0.34-1.93; p=0.63) and morbidity (OR 1.45, 95% CI 0.89-2.35; p=0.13) were similar between the two groups. Data from individual studies showed that male sexual dysfunction and urinary dysfunction (three studies: OR 3.70, 95% CI 1.66-8.23; p=0.0012) were more prevalent in the EL group. There were no significant differences in 5-year survival (hazard ratio [HR] 1.09, 95% CI 0.78-1.50; p=0.62), 5-year disease-free survival (HR 1.23, 95% CI 0.75-2.03, p=0.41), and local (OR 0.83, 95% CI 0.61-1.13; p=0.23) or distant recurrence (OR 0.93, 95% CI 0.72-1.21; p=0.60).
Extended lymphadenectomy does not seem to confer a significant overall cancer-specific advantage, but does seem to be associated with increased urinary and sexual dysfunction.
10% - 25%的直肠癌患者会出现侧方盆腔淋巴结转移,这与更高的局部复发率和更低的生存率相关。我们进行了一项荟萃分析,以评估扩大侧方盆腔淋巴结清扫术在直肠癌手术治疗中的价值。
我们检索了Medline、Embase、Ovid、Cochrane图书馆和谷歌学术,查找1965年至2009年间发表的比较扩大淋巴结清扫术(EL)与标准直肠癌切除术的研究。20项研究符合我们的检索标准并被评估,这些研究包括1984年至2009年间发表的1项随机、3项前瞻性非随机和14项回顾性病例对照研究中的5502例患者。2577例患者因直肠癌接受了EL,2925例患者接受了非EL。在适当情况下使用随机和固定效应荟萃分析模型,并评估研究间的异质性。评估的终点包括围手术期结果、5年生存率和复发率。
EL组的手术时间显著延长76.7分钟(95%可信区间18.77 - 134.68;p = 0.0096)。EL组的术中失血量多536.5毫升(95%可信区间353.7 - 719.2;p < 0.0001)。两组的围手术期死亡率(比值比[OR]0.81,95%可信区间
0.34 - 1.93;p = 0.63)和发病率(OR 1.45,95%可信区间0.89 - 2.35;p = 0.13)相似。个别研究的数据显示,EL组男性性功能障碍和排尿功能障碍(三项研究:OR 3.70,95%可信区间1.66 - 8.23;p = 0.0012)更为普遍。5年生存率(风险比[HR]1.09,95%可信区间0.78 - 1.50;p = 0.62)、5年无病生存率(HR 1.23,95%可信区间0.75 - 2.03,p = 0.41)以及局部(OR 0.83,95%可信区间0.61 - 1.13;p = 0.23)或远处复发(OR 0.93,95%可信区间0.72 - 1.21;p = 0.60)方面均无显著差异。
扩大淋巴结清扫术似乎并未带来显著的总体癌症特异性优势,但似乎与排尿和性功能障碍增加有关。